MBIO - Mustang Bio Corp Company Cash Volume

Corporate company logo of Mustang Bio Corp (MBIO)

Mustang Bio, Inc. (MBIO) focuses on developing gene therapies for rare tumors, with business sustainability depending on clinical trial outcomes. This chart on GURU.Markets shows that cash reserves are trending downward, and the 0.01 mark characterizes this parameter. A lack of pricing power and the sale of assets confirm a capital deficit, although the biotech sector remains non-cyclical and macro-resilient.

mustangbio.com - MBIO Company Liquid Assets (period 07/04/2022 - 11/21/2026)

Analytical breakdowns for Mustang Bio, Inc. (MBIO)

- stock value and consensus price forecast:
Basic company analysis:MBIO Mustang Bio
Brand item of Mustang Bio Corp

This indicator measures liquid capital reserves, allowing for an assessment of the business's financial autonomy and its ability to withstand market volatility without emergency borrowing. By analyzing the cash balance on GURU.Markets, which currently stands at 0.01, an investor can compare the volume of reserves against the development costs of CAR-T therapy for Mustang Bio, Inc. (MBIO) to determine if resources are sufficient to monetize the patent portfolio before achieving commercial success.

Competitors of Mustang Bio, Inc. (MBIO)

Company Cash Volume TEM|QGEN - Company Cash Reserve|ionispharma.com - Company Cash on Hand|Company Cash Balance RGEN|Avidity Corp - Company Cash Volume|CRISPR Therapeutics Corp - Company Total Cash Amount|GeneDx Holdings (WGS) - Company Cash Funds|Ultragenyx Pharmaceutical (RARE) - Company Cash Volume|Company Cash on Hand BEAM|Sarepta (SRPT) - Company Liquid Assets|Company Cash Funds Twist Bioscience Corp (TWST)|10x - Company Cash and Cash Equivalents|Company Cash Volume NTLA (intelliatx.com)|Company Total Cash Amount STOK (stoketherapeutics.com)|BioLife Solutions Inc - Company Cash Volume|WVE (Wave Life Sciences Ltd) - Company Cash and Cash Equivalents|Maze Therapeutics Corp (MAZE) - Company Cash Funds|Company Cash and Cash Equivalents SION|PRME (Prime Medicine Inc) - Company Cash Volume|Taysha Gene Therapies (TSHA) - Company Liquid Assets|Company Cash on Hand QURE (uniqure.com)|Company Total Cash Amount MGTX|Company Cash Volume RGNX (regenxbio.com)|SLDB: Company Cash and Cash Equivalents|ocugen.com - Company Cash Volume|PACB - Company Cash Volume|BNTC: Company Cash Volume|Company Cash and Cash Equivalents DSGN|Company Cash Funds Rocket Pharmaceuticals|Company Cash on Hand 4DMT (FDMT)|Company Cash Volume LXEO|Company Liquid Assets Korro Bio Inc.|Company Cash Volume EDIT (Editas Medicine Inc)|SLN: Company Cash and Cash Equivalents|PRQR - Company Cash Funds|Company Liquid Assets codexis.com CDXS|SGMO: Company Cash Volume|Nautilus Biotechnology (NAUT) - Company Cash Volume|Company Cash Funds Metagenomi, Inc|precisionbiosciences.com (DTIL) - Company Liquid Assets|Company Cash Funds Generation Bio Co. (GBIO)|Company Liquid Assets Boundless Bio, Inc.|Company Cash Funds Exicure, Inc. XCUR|IMNN: Company Cash and Cash Equivalents|PHIO - Company Cash Funds|Company Cash Reserve transcodetherapeutics.com|BNGO: Company Cash Volume|Company Cash and Cash Equivalents APDN|BLUE (bluebirdbio.com) - Company Cash Volume|Company Cash Reserve ImmunoPrecise Antibodies IPA|Company Cash on Hand OMGA (omegatherapeutics.com)|Company Cash Volume Singular Genomics Systems, Inc. (OMIC)|Company Cash Volume RGLS (Regulus Therapeutics, Inc.)|Company Cash Volume Syros SYRS|Telesis Bio, Inc. - Company Cash Volume|TRACON Pharmaceuticals (TCON) - Company Cash on Hand|UBX: Company Cash Volume